Le Lézard
Classified in: Health
Subject: SVY

Global Nuclear Medicine/Radiopharmaceuticals Market, 2018-2024: Increase In Research Activities - Pharmaceuticals And Biotechnology Sectors


DUBLIN, July 18, 2018 /PRNewswire/ --

The "Nuclear Medicine/Radiopharmaceuticals Global Market - Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global nuclear medicine/radiopharmaceutical market is expected to reach $9,275.3 million by 2022

Over the past 50 years nuclear medicine sector has displayed a strong link between investments in chemistry and development of radionuclide's and radiolabeled compounds. This advancement has majorly impacted the health care practice. In the present scenario nuclear medicine is considered to be one of the diagnostics and therapeutic modality technique for probing, tracking and treating disease-related tissue function, progression and treatment response.

Non-invasive nuclear medicine imaging technique provides functional information at both molecular and cellular level and helps measuring the uptake and turnover of target-specific radiotracers in tissue.

Radioisotopes are used in a wide variety of applications like oncology, cardiovascular and neurological disorders. But in recent times, advancements in the field of nuclear medicine and radioactive tracers have emerged to provide few practical methods for studying the limited metabolic activities of bones and teeth, hence has found a role in dental science research.

Nuclear medicinal market is mainly classified into type (diagnosis & therapeutics), application and end-users. The global nuclear medicine market by diagnosis is further divided into SPECT and PET while therapeutics market is segmented into alpha radiation therapy, beta radiation therapy and brachytherapy.

The nuclear medicine/radiopharmaceuticals market is expected to grow at single digit CAGR during 2015 to 2022. The factors driving the growth of this market are increased application of radiopharmaceuticals, rise in public awareness, usage of hybrid imaging, abundance of radio pharmaceuticals, technological advancements; alpha radio immunotherapy based targeted cancer treatment and wide range of available products likely to propel the nuclear medicine market.

In addition to this, increasing need in emerging markets, production of radio pharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes, increasing therapeutic application areas and replacement of old/traditional equipment are some of the opportunities that are propelling the growth of the market. However, regulatory issues, high cost and supply shortage of isotopes, shorter half life of radiopharmaceuticals, and threat from traditional/alternative diagnostic procedures are hampering the growth of the market.

The threats for the nuclear medicine/radiopharmaceuticals market include huge capital investment and shortage of qualified technicians. The major problem area of nuclear medicine market is closure of reactors.

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Take Aways
2.2 Report Scope
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
3.3.1.1 Increased Applications Of Radiopharmaceuticals
3.3.1.2 Rise In Public Awareness
3.3.1.3 Usage Of Hybrid Imaging
3.3.1.4 Technological Advancements
3.3.1.5 Increasing Needs In Emerging Markets
3.3.1.6 Production Of Radiopharmaceuticals From Cyclotrons
3.3.1.7 Efficient Diagnosis And Treatments
3.3.2 Restraints And Threats
3.3.2.1 Shorter Half-Life Of Radiopharmaceuticals
3.3.2.2 High Cost And Supply Shortage Of Isotopes
3.3.2.3 Radio Toxicity
3.3.2.4 Shortage Of Qualified Technicians
3.3.2.5 Regulatory Issues
3.3.2.6 Threat From Traditional/Alternative Diagnostic Procedures
3.3.2.7 Huge Capital Investment
3.4 Problem Areas
3.4.1 Closure Of Reactors
3.5 Winning Imperatives
3.5.1 Availability Of Technetium
3.6 Regulatory Guidelines
3.7 Reimbursement Scenario And Challenges
3.8 Clinical Trials
3.9 Patent Trends
3.10 Supply Chain Analysis
3.10.1 Reactors
3.10.2 Processing Facility
3.10.3 Generators Manufacturing Units
3.10.4 Hospitals And Central Radio Pharmacies
3.11 List Of Potential New Reactors
3.12 List Of FDA Approved Radiopharmaceuticals
3.13 Porter's Five Force Analysis
3.13.1 Threat Of New Entrants
3.13.2 Threat Of Substitutes
3.13.3 Bargaining Power Of Suppliers
3.13.4 Bargaining Power Of Buyers
3.13.5 Competitive Rivalry
3.14 Market Share Analysis By Major Players
3.14.1 Nuclear Medicine Market
3.14.2 Spect Market
3.14.3 Pet Market
3.14.4 Tc-99 Market

4 Nuclear Medicine Global Market, By Modality
4.1 Introduction
4.2 Diagnostics
4.2.1 Radiopharmaceuticals For Diagnosis, By Isotopes
4.2.1.1 Spect, By Isotopes
4.2.1.1.1 Technetium (Tc-99M)
4.2.1.1.2 Thallium (Tl-201)
4.2.1.1.3 Gallium (Ga-67)
4.2.1.1.4 Iodine (I-123)
4.2.1.1.5 Samarium (Sm-153)
4.2.1.1.6 Yttrium (Y-90)
4.2.1.1.7 Rhenium (Re-186)
4.2.1.1.8 Others
4.2.1.2 Pet, By Isotopes
4.2.1.2.1 Fluorodeoxyglucose (18F-Fdg)
4.2.1.2.2 Gallium (Ga-68)
4.2.1.2.3 Rubidium (Rb-82)
4.2.1.2.4 Others
4.2.2 Nuclear Medicine For Diagnosis, By Application
4.2.2.1 Spect By Application
4.2.2.1.1 Cardiology
4.2.2.1.2 Pulmonary
4.2.2.1.3 Oncology
4.2.2.1.4 Nephrology
4.2.2.1.5 Neurology
4.2.2.1.6 Inflammation
4.2.2.1.7 Thyroid Glands
4.2.2.1.8 Lymphology
4.2.2.1.9 Others
4.2.2.2 Pet By Application
4.2.2.2.1 Oncology
4.2.2.2.2 Neurology
4.2.2.2.3 Cardiology
4.2.2.2.4 Inflammation
4.2.2.2.5 Others
4.3 Therapeutics
4.3.1 Nuclear Medicine For Therapeutics, By Radiation Type
4.3.1.1 Beta Radiation Therapy
4.3.1.1.1 Yttrium (Y-90)
4.3.1.1.2 Iodine (I-131)
4.3.1.1.3 Lutetium (Lu-177)
4.3.1.1.4 Samarium (Sm-153)
4.3.1.1.5 Rhenium (Re-186)
4.3.1.1.6 Strontium (Sr-89)
4.3.1.1.7 Erbium (Er-169)
4.3.1.1.8 Others
4.3.1.2 Alpha Radiation Therapy, By Isotopes
4.3.1.3 Brachytherapy, By Isotopes
4.3.1.3.1 Iodine (I-125)
4.3.1.3.2 Cesium (Cs-131)
4.3.1.3.3 Iridium (Ir-192)
4.3.1.3.4 Palladium (Pd-103)
4.3.1.3.5 Others
4.3.2 Nuclear Medicine Therapeutics, By Application
4.3.2.1 Prostate Cancer
4.3.2.2 Thyroid Cancer
4.3.2.3 Liver Cancer
4.3.2.4 Gep-Net Therapeutics
4.3.2.5 Metastatic Bone Cancer Therapeutics
4.3.2.6 Breast Cancer Therapeutics
4.3.2.7 Other Therapeutic Applications

5 Nuclear Medicine Global Market, By End-Users
5.1 Introduction
5.2 Hospital
5.3 Ambulator-Y Centers
5.4 Diagnostic Centers
5.5 Other End-Users

6 Stable Isotopes
6.1 Introduction
6.2 Market Analysis
6.2.1 Factors Influencing Market
6.2.2 Drivers And Opportunities
6.2.2.1 Increase In Research Activities (Pharmaceuticals And Biotechnology Sectors)
6.2.2.2 Increasing Applications
6.2.3 Restraints And Threats
6.2.3.1 High Cost Of Stable Isotopes
6.2.3.2 Stable Isotopes-Side Effects And Safety Issues
6.2.3.3 Stringent Regulations For Manufacturing And Use Of Stable Isotopes
6.3 Stable Isotopes Market, By Isotope
6.3.1 Carbon (C-13)
6.3.2 Deuterium (D2)
6.3.3 Oxygen (O-18)
6.3.4 Nitrogen (N-15)
6.3.5 Sulphur (S-32)
6.3.6 Others
6.4 Stable Isotopes Market, By Application
6.4.1 Introduction
6.4.2 Diagnostics And Therapy
6.4.3 Pharmaceuticals
6.4.4 Others
6.5 Stable Isotopes Market, By Geography
6.5.1 Introduction
6.5.2 North America
6.5.3 Europe
6.5.4 Asia-Pacific
6.5.5 Rest Of The World

7 Regional Analysis

8 Competitive Landscape
8.1 Introduction
8.2 Approvals And Agreements
8.3 Acquisition, Expansion And Collaboration
8.4 Others Developments

9 Major Player Profiles

For more information about this report visit https://www.researchandmarkets.com/research/7z5826/global_nuclear?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:


Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 17:55
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated Announces Increased First Quarter Dividend
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...

at 17:31
Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsight
DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market...

at 17:00
Enghouse Video Partners With SONIFI Health To Deliver Advanced Telehealth Solutions In Hospital Rooms
Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings. SONIFI Health is a leading U.S. healthcare technology company based in Sioux...

at 17:00
2024 R-1 Main Residency Match results released
A record 3,618 graduating students and physicians matched to residency training programs in Canada in this year's R-1 Main Residency Match (R-1 match), the Canadian Resident Matching Service (CaRMS) announced today....

at 16:54
Hondros College of Nursing Announces Launch of Medical Assisting Program
Hondros College of Nursing (HCN) will introduce a new Medical Assisting program at its six Ohio campuses in 2024 to meet the growing need for medical assistants in a variety of settings.  According to the U.S. Bureau of Labor Statistics (BLS),...

More news about Health...


News published on and distributed by: